ArticleThe American journal of emergency medicine2015
Exploratory study on association of single-nucleotide polymorphisms with hydromorphone analgesia in ED.
Article in The American journal of emergency medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 6 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe objective of this study is to provide information on distribution of important single-nucleotide polymorphisms (SNPs) and evaluate their associations with clinical response to intravenous hydromorphone in emergency department.
methodsA prospective exploratory study was performed. A convenience sample of adult emergency department patients with acute pain deemed to require intravenous opioids received 1 mg of intravenous hydromorphone. Primary outcome was pain score (numeric rating scale, NRS) reduction between baseline and 30 minutes after medication administration. Secondary outcomes were pain relief, patient satisfaction with analgesia, desire for more analgesics, and side effects (nausea, vomiting, and pruritis). Single-nucleotide polymorphisms in OPRM1 gene (opioid receptor, A118G), ABCB1 gene (opioid transporter, C3435T), COMT gene (pain sensitivity, G1947A), and UGT2B7 gene (opioid metabolism, -G840A) were tested. We used Kruskal-Wallis test to compare the primary outcome and χ(2) test (or Fisher test) to compare the secondary outcomes among patients carrying different SNPs.
resultsOne thousand four hundred thirty-eight patients were screened, and 163 patients were enrolled in the study. The mean age was 39 years. Sixty-three percent were female, 58% were Hispanic, and 67% had pain located in abdomen. The median pain NRS reduction at 30 minutes was 5 (interquartile range, 3-8). There was no difference in pain NRS reduction among patients carrying different SNPs. Secondary outcome analysis revealed statistically significant associations between patient satisfaction with treatment and OPRM1 and between nausea and UGT2B7.
conclusionsThis exploratory study did not show a significant difference in pain NRS reduction among patients carrying different SNPs. Patient satisfaction with analgesia and nausea were statistically significantly associated with OPRM1 and UGT2B7, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.